{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:56:21Z","timestamp":1792443381880,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS111102"],"award-info":[{"award-number":["R01NS111102"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS119609"],"award-info":[{"award-number":["R01NS119609"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R03NS135450"],"award-info":[{"award-number":["R03NS135450"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R21EY034677"],"award-info":[{"award-number":["R21EY034677"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13346-025-01944-3","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T16:27:39Z","timestamp":1755707259000},"page":"894-910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson\u2019s disease"],"prefix":"10.1007","volume":"16","author":[{"given":"Mohit","family":"Kwatra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6908-9638","authenticated-orcid":false,"given":"Gijung","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5376-7657","authenticated-orcid":false,"given":"Jung Soo","family":"Suk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0864-5239","authenticated-orcid":false,"given":"Han Seok","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"1944_CR1","volume-title":"Parkinson\u2019s disease: pathogenesis and clinical aspects","author":"A Kouli","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan WL. Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson\u2019s disease: pathogenesis and clinical aspects. Editors: Brisbane (AU) 2018."},{"key":"1944_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fnins.2018.00080","volume":"12","author":"JC Bridi","year":"2018","unstructured":"Bridi JC, Hirth F. Mechanisms of alpha-Synuclein induced synaptopathy in parkinson\u2019s disease. Front Neurosci. 2018;12:80.","journal-title":"Front Neurosci"},{"issue":"1","key":"1944_CR3","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, et al. Parkinson disease. Nat Reviews Disease Primers. 2017;3(1):17013.","journal-title":"Nat Reviews Disease Primers"},{"issue":"1","key":"1944_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2169\/internalmedicine.8940-21","volume":"62","author":"H Murakami","year":"2023","unstructured":"Murakami H, et al. Recent advances in drug therapy for parkinson\u2019s disease. Intern Med. 2023;62(1):33\u201342.","journal-title":"Intern Med"},{"issue":"8","key":"1944_CR5","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/brain\/awaa181","volume":"143","author":"R Cilia","year":"2020","unstructured":"Cilia R, et al. Natural history of motor symptoms in parkinson\u2019s disease and the long-duration response to Levodopa. Brain. 2020;143(8):2490\u2013501.","journal-title":"Brain"},{"issue":"3","key":"1944_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2174\/1570159X16666180905094123","volume":"17","author":"YA Sidorova","year":"2019","unstructured":"Sidorova YA, Volcho KP, Salakhutdinov NF. Neuroregeneration in parkinson\u2019s disease: from proteins to small molecules. Curr Neuropharmacol. 2019;17(3):268\u201387.","journal-title":"Curr Neuropharmacol"},{"key":"1944_CR7","doi-asserted-by":"crossref","unstructured":"Kwon DK et al. Levodopa-Induced Dyskinesia in Parkinson\u2019s Disease: Pathogenesis and Emerging Treatment Strategies. Cells, 2022. 11(23).","DOI":"10.3390\/cells11233736"},{"issue":"12","key":"1944_CR8","doi-asserted-by":"publisher","first-page":"167932","DOI":"10.1016\/j.jmb.2022.167932","volume":"435","author":"R Machtel","year":"2023","unstructured":"Machtel R, et al. From lysosomal storage disorders to parkinson\u2019s Disease - Challenges and opportunities. J Mol Biol. 2023;435(12):167932.","journal-title":"J Mol Biol"},{"issue":"3","key":"1944_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.14802\/jmd.23023","volume":"16","author":"YE Huh","year":"2023","unstructured":"Huh YE, et al. GBA1 variants and parkinson\u2019s disease: paving the way for targeted therapy. J Mov Disord. 2023;16(3):261\u201378.","journal-title":"J Mov Disord"},{"issue":"17","key":"1944_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"issue":"1","key":"1944_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00441-017-2704-y","volume":"373","author":"I Stojkovska","year":"2018","unstructured":"Stojkovska I, Krainc D, Mazzulli JR. Molecular mechanisms of alpha-synuclein and GBA1 in parkinson\u2019s disease. Cell Tissue Res. 2018;373(1):51\u201360.","journal-title":"Cell Tissue Res"},{"key":"1944_CR12","doi-asserted-by":"crossref","unstructured":"Baden P et al. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism. Nat Commun, 2023;14(1):1930.","DOI":"10.1038\/s41467-023-37454-4"},{"issue":"1","key":"1944_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37\u201352.","journal-title":"Cell"},{"issue":"8","key":"1944_CR14","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1093\/brain\/awae070","volume":"147","author":"JC Rubilar","year":"2024","unstructured":"Rubilar JC, Outeiro TF, Klein AD. The lysosomal beta-glucocerebrosidase strikes mitochondria: implications for parkinson\u2019s therapeutics. Brain. 2024;147(8):2610\u201320.","journal-title":"Brain"},{"issue":"6","key":"1944_CR15","doi-asserted-by":"publisher","first-page":"eabm6393","DOI":"10.1126\/sciadv.abm6393","volume":"8","author":"SH Kuo","year":"2022","unstructured":"Kuo SH, et al. Mutant glucocerebrosidase impairs alpha-synuclein degradation by Blockade of chaperone-mediated autophagy. Sci Adv. 2022;8(6):eabm6393.","journal-title":"Sci Adv"},{"issue":"4","key":"1944_CR16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1073\/pnas.1700465115","volume":"115","author":"S Kim","year":"2018","unstructured":"Kim S, et al. GBA1 deficiency negatively affects physiological \u03b1-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A. 2018;115(4):798\u2013803.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1944_CR17","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1038\/ncomms5028","volume":"5","author":"DC Schondorf","year":"2014","unstructured":"Schondorf DC, et al. iPSC-derived neurons from GBA1-associated parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun. 2014;5:4028.","journal-title":"Nat Commun"},{"issue":"12","key":"1944_CR18","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1093\/brain\/awae222","volume":"147","author":"SH Kweon","year":"2024","unstructured":"Kweon SH, et al. Gba1 E326K renders motor and non-motor symptoms with pathological alpha-synuclein, Tau and glial activation. Brain. 2024;147(12):4072\u201383.","journal-title":"Brain"},{"issue":"4","key":"1944_CR19","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1073\/pnas.1700465115","volume":"115","author":"S Kim","year":"2018","unstructured":"Kim S, et al. GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A. 2018;115(4):798\u2013803.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1944_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40478-018-0538-9","volume":"6","author":"D Kim","year":"2018","unstructured":"Kim D, et al. D409H GBA1 mutation accelerates the progression of pathology in A53T alpha-synuclein Transgenic mouse model. Acta Neuropathol Commun. 2018;6(1):32.","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"1944_CR21","doi-asserted-by":"publisher","first-page":"e0238075","DOI":"10.1371\/journal.pone.0238075","volume":"15","author":"A Migdalska-Richards","year":"2020","unstructured":"Migdalska-Richards A, et al. L444P Gba1 mutation increases formation and spread of alpha-synuclein deposits in mice injected with mouse alpha-synuclein pre-formed fibrils. PLoS ONE. 2020;15(8):e0238075.","journal-title":"PLoS ONE"},{"issue":"1","key":"1944_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","volume":"14","author":"J Do","year":"2019","unstructured":"Do J, et al. Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 2019;14(1):36.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"1944_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg ME, et al. Glucocerebrosidase deficiency in substantia Nigra of Parkinson disease brains. Ann Neurol. 2012;72(3):455\u201363.","journal-title":"Ann Neurol"},{"issue":"23","key":"1944_CR24","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1016\/j.neuron.2021.09.031","volume":"109","author":"BA Seo","year":"2021","unstructured":"Seo BA, et al. TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in parkinson\u2019s disease. Neuron. 2021;109(23):3758\u2013e377411.","journal-title":"Neuron"},{"key":"1944_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","volume":"82","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, et al. Glucocerebrosidase gene therapy prevents \u03b1-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015;82:495\u2013503.","journal-title":"Neurobiol Dis"},{"issue":"12","key":"1944_CR26","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2017.08.004","volume":"25","author":"G Morabito","year":"2017","unstructured":"Morabito G, et al. AAV-PHP.B-Mediated Global-Scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy. Mol Ther. 2017;25(12):2727\u201342.","journal-title":"Mol Ther"},{"key":"1944_CR27","doi-asserted-by":"crossref","unstructured":"Sucunza D et al. Glucocerebrosidase gene therapy induces Alpha-Synuclein clearance and neuroprotection of midbrain dopaminergic neurons in mice and macaques. Int J Mol Sci, 2021;22(9).","DOI":"10.3390\/ijms22094825"},{"issue":"1","key":"1944_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-017-0233-5","volume":"13","author":"SP Yun","year":"2018","unstructured":"Yun SP, et al. alpha-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener. 2018;13(1):1.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"1944_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang JH, et al. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9(1):78.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1944_CR30","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.drudis.2019.01.019","volume":"24","author":"JJ Darrow","year":"2019","unstructured":"Darrow JJ. Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discov Today. 2019;24(4):949\u201354.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1944_CR31","first-page":"6","volume":"24","author":"A Mullard","year":"2025","unstructured":"Mullard A. FDA approves L-amino acid decarboxylase deficiency gene therapy. Nat Rev Drug Discov. 2025;24(1):6.","journal-title":"Nat Rev Drug Discov"},{"key":"1944_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jconrel.2017.07.009","volume":"262","author":"P Mastorakos","year":"2017","unstructured":"Mastorakos P, et al. Biodegradable brain-penetrating DNA nanocomplexes and their use to treat malignant brain tumors. J Control Release. 2017;262:37\u201346.","journal-title":"J Control Release"},{"issue":"3","key":"1944_CR33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s13346-020-00759-8","volume":"10","author":"K Negron","year":"2020","unstructured":"Negron K, et al. Non-adhesive and highly stable biodegradable nanoparticles that provide widespread and safe transgene expression in orthotopic brain tumors. Drug Deliv Transl Res. 2020;10(3):572\u201381.","journal-title":"Drug Deliv Transl Res"},{"issue":"38","key":"1944_CR34","doi-asserted-by":"publisher","first-page":"17869","DOI":"10.1039\/C9NR02858G","volume":"11","author":"R Riera","year":"2019","unstructured":"Riera R, et al. Tracking the DNA complexation state of pBAE polyplexes in cells with super resolution microscopy. Nanoscale. 2019;11(38):17869\u201377.","journal-title":"Nanoscale"},{"issue":"10","key":"1944_CR35","doi-asserted-by":"publisher","first-page":"5930","DOI":"10.1021\/nn100968e","volume":"4","author":"J Sankaranarayanan","year":"2010","unstructured":"Sankaranarayanan J, et al. Multiresponse strategies to modulate burst degradation and release from nanoparticles. ACS Nano. 2010;4(10):5930\u20136.","journal-title":"ACS Nano"},{"issue":"10","key":"1944_CR36","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/17425247.2020.1796628","volume":"17","author":"J Karlsson","year":"2020","unstructured":"Karlsson J, et al. Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities. Expert Opin Drug Deliv. 2020;17(10):1395\u2013410.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"1944_CR37","doi-asserted-by":"publisher","first-page":"eabk2855","DOI":"10.1126\/sciadv.abk2855","volume":"8","author":"Y Rui","year":"2022","unstructured":"Rui Y, et al. High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA. Sci Adv. 2022;8(1):eabk2855.","journal-title":"Sci Adv"},{"issue":"35","key":"1944_CR38","doi-asserted-by":"publisher","first-page":"24139","DOI":"10.1021\/acsnano.4c05270","volume":"18","author":"G Kwak","year":"2024","unstructured":"Kwak G, et al. Brain nucleic acid delivery and genome editing via focused Ultrasound-Mediated Blood-Brain barrier opening and Long-Circulating nanoparticles. ACS Nano. 2024;18(35):24139\u201353.","journal-title":"ACS Nano"},{"issue":"8","key":"1944_CR39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrg3763","volume":"15","author":"H Yin","year":"2014","unstructured":"Yin H, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541\u201355.","journal-title":"Nat Rev Genet"},{"issue":"12","key":"1944_CR40","doi-asserted-by":"publisher","first-page":"eaay3255","DOI":"10.1126\/sciadv.aay3255","volume":"5","author":"Y Rui","year":"2019","unstructured":"Rui Y, et al. Carboxylated branched poly(beta-amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci Adv. 2019;5(12):eaay3255.","journal-title":"Sci Adv"},{"issue":"1","key":"1944_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3171\/2016.1.JNS151591","volume":"126","author":"A Jahangiri","year":"2017","unstructured":"Jahangiri A, et al. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg. 2017;126(1):191\u2013200.","journal-title":"J Neurosurg"},{"issue":"9","key":"1944_CR42","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2014.143","volume":"9","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley LA, Luk KC, Lee VM. Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to lewy body and lewy neurite-like aggregates. Nat Protoc. 2014;9(9):2135\u201346.","journal-title":"Nat Protoc"},{"issue":"7","key":"1944_CR43","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH image to imageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671\u20135.","journal-title":"Nat Methods"},{"issue":"7","key":"1944_CR44","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of parkinson\u2019s disease. Nat Med. 2018;24(7):931\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"1944_CR45","doi-asserted-by":"publisher","first-page":"e15622","DOI":"10.1016\/j.heliyon.2023.e15622","volume":"9","author":"H Zhang","year":"2023","unstructured":"Zhang H, et al. Air pollution nanoparticle and alpha-synuclein fibrils synergistically decrease glutamate receptor A1, depending upon nPM batch activity. Heliyon. 2023;9(4):e15622.","journal-title":"Heliyon"},{"key":"1944_CR46","doi-asserted-by":"crossref","unstructured":"Quansah E et al. \u2009Tet2\u2009loss suppress \u03b1-synuclein pathology by stimulating ciliogenesis. bioRxiv, 2024;2024.08.02.606408.","DOI":"10.1101\/2024.08.02.606408"},{"key":"1944_CR47","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bbi.2020.09.017","volume":"91","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, et al. Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of parkin-mediated mitophagy in in-vitro and in-vivo models of Parkinson disease. Brain Behav Immun. 2021;91:142\u201358.","journal-title":"Brain Behav Immun"},{"key":"1944_CR48","doi-asserted-by":"publisher","first-page":"104835","DOI":"10.1016\/j.neuint.2020.104835","volume":"140","author":"M Kwatra","year":"2020","unstructured":"Kwatra M, et al. Hesperidin alleviates chronic restraint stress and lipopolysaccharide-induced hippocampus and frontal cortex damage in mice: role of TLR4\/NF-\u03baB, p38 MAPK\/JNK, Nrf2\/ARE signaling. Neurochem Int. 2020;140:104835.","journal-title":"Neurochem Int"},{"key":"1944_CR49","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jpsychires.2021.10.021","volume":"144","author":"M Kwatra","year":"2021","unstructured":"Kwatra M, et al. Lipopolysaccharide exacerbates chronic restraint stress-induced neurobehavioral deficits: mechanisms by redox imbalance, ASK1-related apoptosis, autophagic dysregulation. J Psychiatr Res. 2021;144:462\u201382.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"1944_CR50","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim S, et al. Transneuronal propagation of pathologic alpha-Synuclein from the gut to the brain models parkinson\u2019s disease. Neuron. 2019;103(4):627\u2013e6417.","journal-title":"Neuron"},{"issue":"1","key":"1944_CR51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1021\/acschemneuro.1c00550","volume":"13","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, et al. Perillyl alcohol attenuates NLRP3 inflammasome activation and rescues dopaminergic neurons in experimental in vitro and in vivo models of parkinson\u2019s disease. ACS Chem Neurosci. 2022;13(1):53\u201368.","journal-title":"ACS Chem Neurosci"},{"issue":"15","key":"1944_CR52","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.neuron.2022.05.009","volume":"110","author":"N Panicker","year":"2022","unstructured":"Panicker N, et al. Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in parkinson\u2019s disease. Neuron. 2022;110(15):2422\u2013e24379.","journal-title":"Neuron"},{"key":"1944_CR53","doi-asserted-by":"publisher","first-page":"104183","DOI":"10.1016\/j.etap.2023.104183","volume":"101","author":"SR Panda","year":"2023","unstructured":"Panda SR, et al. Ambient particulate matter (PM(2.5)) exposure contributes to neurodegeneration through the microbiome-gut-brain axis: therapeutic role of melatonin. Environ Toxicol Pharmacol. 2023;101:104183.","journal-title":"Environ Toxicol Pharmacol"},{"issue":"2","key":"1944_CR54","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JPD-171248","volume":"8","author":"NK Polinski","year":"2018","unstructured":"Polinski NK, et al. Best practices for generating and using Alpha-Synuclein Pre-Formed fibrils to model parkinson\u2019s disease in rodents. J Parkinsons Dis. 2018;8(2):303\u201322.","journal-title":"J Parkinsons Dis"},{"issue":"9","key":"1944_CR55","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41565-018-0179-y","volume":"13","author":"D Kim","year":"2018","unstructured":"Kim D, et al. Graphene quantum Dots prevent alpha-synucleinopathy in parkinson\u2019s disease. Nat Nanotechnol. 2018;13(9):812\u20138.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"1944_CR56","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1038\/s41598-019-42399-0","volume":"9","author":"K Kakuda","year":"2019","unstructured":"Kakuda K, et al. Ultrasonication-based rapid amplification of \u03b1-synuclein aggregates in cerebrospinal fluid. Sci Rep. 2019;9(1):6001.","journal-title":"Sci Rep"},{"key":"1944_CR57","doi-asserted-by":"crossref","unstructured":"Sulatskaya AI et al. Investigation of \u03b1-Synuclein amyloid fibrils using the fluorescent probe thioflavin T. Int J Mol Sci, 2018;19(9).","DOI":"10.3390\/ijms19092486"},{"issue":"3","key":"1944_CR58","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1006\/bbrc.1996.1112","volume":"224","author":"Y Imai","year":"1996","unstructured":"Imai Y, et al. A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun. 1996;224(3):855\u201362.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1944_CR59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1750-3639.1994.tb00838.x","volume":"4","author":"LF Eng","year":"1994","unstructured":"Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol. 1994;4(3):229\u201337.","journal-title":"Brain Pathol"},{"key":"1944_CR60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fnmol.2015.00077","volume":"8","author":"RH Shih","year":"2015","unstructured":"Shih RH, Wang CY, Yang CM. NF-kappaB signaling pathways in neurological inflammation: A mini review. Front Mol Neurosci. 2015;8:77.","journal-title":"Front Mol Neurosci"},{"issue":"442","key":"1944_CR61","doi-asserted-by":"publisher","first-page":"ra85","DOI":"10.1126\/scisignal.aab2820","volume":"9","author":"JP Pradere","year":"2016","unstructured":"Pradere JP, et al. Negative regulation of NF-kappaB p65 activity by Serine 536 phosphorylation. Sci Signal. 2016;9(442):ra85.","journal-title":"Sci Signal"},{"issue":"5","key":"1944_CR62","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00702-017-1732-9","volume":"125","author":"AS Mendiola","year":"2018","unstructured":"Mendiola AS, Cardona AE. The IL-1beta phenomena in neuroinflammatory diseases. J Neural Transm (Vienna). 2018;125(5):781\u201395.","journal-title":"J Neural Transm (Vienna)"},{"key":"1944_CR63","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.omtm.2023.03.007","volume":"29","author":"Y Peng","year":"2023","unstructured":"Peng Y, et al. iPSC-derived neural precursor cells engineering GBA1 recovers acid beta-glucosidase deficiency and diminishes alpha-synuclein and neuropathology. Mol Ther Methods Clin Dev. 2023;29:185\u2013201.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1944_CR64","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","volume":"26","author":"TY Yang","year":"2022","unstructured":"Yang TY, et al. Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper. Mol Ther Methods Clin Dev. 2022;26:471\u201394.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1944_CR65","doi-asserted-by":"crossref","unstructured":"Huang M, Gu X, Gao X. 13 - Nanotherapeutic strategies for the treatment of neurodegenerative diseases, in Brain targeted drug delivery system. Academic. 2019;321\u201356. H. Gao and X. Gao, Editors.","DOI":"10.1016\/B978-0-12-814001-7.00013-5"},{"key":"1944_CR66","doi-asserted-by":"publisher","first-page":"114583","DOI":"10.1016\/j.addr.2022.114583","volume":"191","author":"CM Gorick","year":"2022","unstructured":"Gorick CM, et al. Applications of focused ultrasound-mediated blood-brain barrier opening. Adv Drug Deliv Rev. 2022;191:114583.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01944-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01944-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01944-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:53:43Z","timestamp":1781614423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01944-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1944"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01944-3","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"30 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with the guidelines and policies of the Institutional Animal Care and Use Committee at Johns Hopkins University or University of Maryland Baltimore.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All of the authors consent to the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}